Epidemiology and Infectious DiseasesEpidemiology and Infectious DiseasesЭпидемиология и инфекционные болезни3034-20073034-2015Eco-Vector4078810.17816/EID40788ArticlesСтатьиResearch ArticleLiver cirrhosis and hepatocellular carcinoma in patients with chronic viral hepatitis c: some epidemiologic and molecular-genetic aspectsЦирроз печени и гепатоклеточная карцинома у пациентов с хроническим вирусным гепатитом С: эпидемиологические и молекулярно-генетические аспектыNikolaevaL. IНиколаеваЛюдмила Ивановна

д-р биол. наук, рук.лаб. генно-инженерных препаратов

L.i.nikolaeva@mail.ruLeybmanE. AЛейбманЕлена Александровна

мл. науч. сотр. лаб. генно-инженерных препаратов; аспирант каф. инфекционных болезней у детей № 1 педиатрического фаультета

dr.leybman@gmail.comSapronovG. VСапроновГеоргий Витальевич

доцент каф. инфекционных болезней

geo8@inbox.ruYudinA. NЮдинАлексей Николаевич

ст. науч. сотр. лаб. генно-инженерных препаратов, канд. биол. наук

alexudin@mail.ruD.I. Ivanovsky Institute of VirologyФГБУ «НИИ вирусологии им. Д.И. Ивановского» Минздрава РоссииN.I. Pirogov Russian National Medical UniversityГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииRussian Medical Academy of Post-Graduate EducationГБОУ ДПО «Российская академия последипломного образования»15042014192NO2 (2014)№2 (2014)405123072020Copyright ©; 2014, Eco-vectorCopyright ©; 2014, ООО "Эко-вектор"2014Eco-vectorООО "Эко-вектор"https://rjeid.com/1560-9529/article/view/40788

The aim of this review is to analyze the modern epidemiological and molecular-genetic data concerning development of liver cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C. There were considered peculiarities of the occurrence of this pathology in adult patients and children with hepatitis C.

Цель обзора - проанализировать современные эпидемиологические и молекулярно-генетические данные по развитию цирроза печени и первичной гепатоклеточной карциномы у пациентов с хроническим вирусным гепатитом С. Рассмотрены особенности распространения этой патологии у взрослых и детей.

viral hepatitis Cliver cirrhosishepatocellular carcinomaвирусный гепатит Сцирроз печенигепатоклеточная карциномаМукомолов С.Л., Левакова И.А., Сулягина Л.Г., Синайская Е.В., Болсун Д.Д., Иванова Н.В. Современная эпидемиология гепатита С в России. https://hepexpert.ru. 2012; 1-6.European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-64.Mosley J.W., Operskalski E.A., Tobler L.H. et al. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005; 42: 86-92.Thomas D.L. Global control of hepatitis C: where challenge meets opportunity. Nature Med. 2013; 19 (7): 850-8.Нечаев В.В., Мукомолов С.Л., Назаров В.Ю. и др. Эволюция эпидемического процесса хронических гепатитов в Санкт- Петербурге. Гастроэнтерология Санкт-Петербурга. 2011; 1: 21-4.Alter M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 2007; 13: 2436-41.Самохвалов Е.И., Николаева Л.И., Альховский С.В. и др. Частота встречаемости отдельных субтипов вируса гепатита С в Московском регионе. Вопросы вирусологии. 2013; 1: 36-40.Thomas D.L., Seeff L.B. The natural history of hepatitis C. Clin. Liver Dis. 2005; 9: 383-98.Kew M.C. The role of cirrhosis in the etiology of hepatocellular carcinoma. J. Gastrointest. Cancer. 2013; PMID: 24203525.Caldwell S., Park S.H. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J. Gastroenterol. 2009; 44 (Suppl. 19): 96-101.Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nature Med. 2013; 19 (7): 859-68.Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennigs L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138: 513-21.Lehman E.M., Wilson M.L. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J. Viral Hepat. 2009; 16: 650-8.Deuffic S., Buffat L., Poynard T., Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999; 29: 1596-601.El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-73.El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-76.Tanaka Y., Kurbanov F., Mano S. Orito E., Vargas V., Esteban J.I. et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006; 130:703-14.Haydon G.H., Jarvis L.M., Simmonds P., Hayes P.C. Association between chronic hepatitis C infection and hepatocellular carcinoma. Lancet. 1995; 345: 928-9.Schvoerer E., Soulier E., Royer C., Renaudin A.C., Thumann C., Fafi-Kremer S. et al. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J. Infect. Dis. 2007; 196: 528-36.Raimondi S., Bruno S., Mondelli M.U., Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009; 50: 1142-54.Wise M., Finelli L., Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Publ. Hlth Rep. 2010; 125: 414-22.Yuan J.M., Ross R.K., Stanczyk F.Z., Govindarajan S., Gao Y.T., Henderson B.E., Yu M.C. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int. J. Cancer. 1995; 63: 491-3.Nguyen H.V., Mollison L.C., Taylor T.W., Chubb S.A., Yeap B.B. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern. Med. J. 2006; 36: 362-6.Tanaka K., Sakai H., Hashizume M., Hirohata T. Serum testosterone: estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res. 2000; 60: 5106-10.White D.L., Tavakoli-Tabasi S., Kuzniarek J., Pascua R., Ramsey D.J., El-Serag H.B. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012; 55: 759-68.Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48 (2): 418-31.Brunt P.W., Kew M.C., Scheuer P.J., Sherlock S. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut. 1974; 1: 52-8.Лопаткина Т.Н., Танащук Е.Л. Алкогольная болезнь печени. Вирусные гепатиты: перспективы и достижения. 2001; 1: 11-6.Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J. A. M. A. 2000; 284: 450-6.Oshita M., Hayashi N., Kashahara A., Hagiwara H., Mita E., Naito M. et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994; 20: 1115-20.Safdar K., Schiff E.R. Alcohol and hepatitis C. Semin. Liver Dis. 2004; 24: 305-15.Moreno-Otero R., Trapero M., Jara P. Liver histology damage in children with chronic hepatitis C. Pediatr. Infect. Dis. J. 2010; 29:189-90.Jonas M.M. Children with hepatitis C. Hepatology. 2002; 36 (Suppl. 1): S173-8.Филимонов П.Н. Патоморфология хронических сочетанных вирусных гепатитов у детей: Дисс. Новосибирск; 2005.Badizadegan K., Jonas M.M., Ott M.J., Nelson S.P., Perez-Atayde A.R. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology. 1998; 28: 1416-23.Delgado-Borrego A., Healey D., Negre B., Christofi M., Sabharwal S., Ludwig D.A. et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J. Pediatr. Gastroenterol. Nutr. 2010; 51: 191-7.Marco V.D., Bronte F., Calvaruso V., Capra M., Borsellino Z., Maggio A. et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica. 2012; 97: 679-86.Broide E., Reif S., Brazovski E., Shapira R., Weiss B., Bujanover Y et al.Chronic hepatitis C in Israeli children. Fetal. Pediatr. Pathol. 2004; 23: 231-9.Abdel-Hady M., Bunn S.K., Sira J., Brown R.M., Brundler M.A., Davies P. et al.Chronic hepatitis C in children - review of natural history at a National Centre. J. Viral Hepat. 2011; 18: 535-40.Gonzalez-Peralta R.P, Langham M.R. Jr., Andres J.M., Mohan P, Colombani P.M., Alford M.K. et al . Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 630-5Строкова Т.В. Клиническое течение и интерферонотерапия хронического гепатита С у детей. Вопросы современной педиатрии. 2002; 2: 17.Mohan P., Colvin C., Glymph C., Chandra R.R., Kleiner D.E., Patel K.M. et al.Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J. Pediatr. 2007; 150: 168-74.Чуелов С.Б., Россина А.Л., Смирнов А.В., Брюсова И.Б., Волкова Г.И., Иванова Ю.Н. и др. Этиологическая структура циррозов печени у детей. Детские инфекции. 2008; 7: 14-8.Каганов Б. С., Зайнудинов З. М., Строкова Т. В., Готье С.В, Цырюльникова О.М. Критерии диагностики и клиническое течение цирроза печени у детей. Инфекционные болезни. 2008; 6: 14-21.Guido M., Bortolotti F., Leandro G., Jara P., Hierro L., Larrauri J. et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am. J. Gastroenterol. 2003; 98: 660-3.Jara P., Resti M., Hierro L., Giacchino R., Barbera C., Zancan L. et al. Chronic hepatitis C virus infection in childhood: Clinical patterns and evolution in 224 white children. Clin. Infect. Dis. 2003; 36: 275-80.Соловьева И.А., Мартынова Г.П., Савченко А.А. Клиникоэпидемиологическая характеристика хронических гепатитов В и С у подростков. Детские инфекции. 2012; 4: 19-22.Iorio R., Giannattasio A., Sepe A., Terracciano L.M., Vecchione R., Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin. Infect. Dis. 2005; 41: 1431-7.Чуелов С.Б., Нисевич Н.И., Гаспарян М.О., Молочкова О.В., Чаплыгина Г.В., Брюсова И.Б. и др. Клиника, диагностика и течение цирроза печени при HCV-инфекции у детей. Детские инфекции. 2005; 1: 22-9.Молочкова О.В., Чередниченко Т.В., Гаспарян М.О., Чаплыгина Г.В. Течение гепатита С у детей. Детские инфекции. 2002; 1: 21-3.Probst A., Dang T., Bochud M., Egger M., Negro F., Bochud P.Y. Role of hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J. Viral Hepat. 2011; 18: 745-59Николаева Л.И., Тойчуев П.М., Лейбман Е.А., Гришечкин А.Е., Оморбекова Ч.Т., Ахмедова Д.П. и др. Факторы, влияющие на течение хронического гепатита Судетей. Эпидемиология и вакцинопрофилактика. 2013; 6: 37-44Bortolotti F., Verucchi G., Camma C., Cabibbo G., Zancan L., In-dolfi G. et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134: 1900-7.Horner S.M., Gale M.Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nature Med. 2013; 19: 879-88.Bowen D.G., Walker C.M. Adaptive immune responses I acute and chronic hepatitis C virus infection. Nature. 2005; 436: 946Senoo H., Yoshikawa K., Morii M., Tmai K., Mezaki Y. Hepatic stellate cell (vitamin A - storing cell) and its relative - past, present and future. Cell Biol. Int. 2010; 34: 1247-72.Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 2003; 28: 105-12.Friedman S.L., Arthur M.J. Activation of cultured rat hepatic lipocytes matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J. Clin. Invest. 1989; 84: 1780-5.Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front. Biosci.: J. Virtual Library. 2009; 14: 2923-34.Satyanarayana A., Manns M.P., Rudolph K.L. Telomeres and te-lomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004; 40: 276-83.Fujio K., Evarts R.P., Hu Z., Marsden E.R., Thorgeirsson S.S. Expression of stem cell factor and its receptor, c-kit, during liver regeneration from putative stem cells in adult rat. Lab. Invest.: J. Techn. Meth. Pathol. 1994; 70: 511-6.Kordes C., Sawitza I., Muller-Marbach A., Ale-Agha N., Keitel V., Klonowski-Stumpe H. et al. CD133+ hepatic stellate cells are progenitor cells. Biochem. Biophys. Res. Commun. 2007; 352: 410-7.Behnke M.K., Reimers M., Fisher R.A. Stem cell and hepatocyte proliferation in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications. Ann. Hepatol. 2013; 13: 45-53.Horl W.H., Schmidt A. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C. Nephrol. Dial. Transplant. 2013; PMDI: 24286977.Pradere J.P., Kluwe J., de Minicis S., Jiao J.J., Gwak G.Y., Dapito D.H. et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting survival of activated hepatic stellate cells in mice. Hepatology. 2013; 58: 1461-73.Branda M., Wands J.R. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology. 2006; 43: 891-902.Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48: 1312-27.Tsai W.L., Chung R.T. Viral hepatocarcinogenesis. Oncogene. 2010; 29: 2309-24.Zekri Ael-R., Nassar A.A., El-Din El-Rouby M.N., Shousha H.I., Barakat A.B., El-Desouky E.D. et al. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac. J. Cancer Prev. 2013; 14: 6721-6.Yamashita T., Honda M., Kaneko S. Application of serial analysis of gene expression in cancer research. Curr. Pharm. Biotech-nol. 2008; 9: 375-82.Honda M., Kaneko S., Kawai H., Shirota Y., Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology. 2001; 120: 955-66.Yamashita T., Kaneko S., Hashimoto S., Sato T., Nagai S., Toyoda N. et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem. Biophys. Res. Com-mun. 2001; 282: 647-54.Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J. Viral Hepat. 2004; 11: 383-93.Akuta N., Suzuki F., Kawamura Y, Yatsuji H., Sezaki H., Suzuki Y et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007; 46: 1357-64.Fishman S.L., Factor S.H., Balestrieri C., Fan X., Dibisceglie A.M., Desai S.M. et al. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin. Cancer Res. 2009; 15: 3205-13.Araujo O.C., Barros J.J., do О K.M., Nabuco L.C., Luz C.A., Perez R.M. et al. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma. J. Med. Virol. 2014; 86: 217-23.Yamanaka T., Kodama T., Doi T. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem. Biophys. Res. Commun. 2002; 294: 528-34.Kwun H.J., Jang K.L. Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J. Viral Hepat. 2003; 10: 249-55.Jeong S.W., Jang J.Y., Chung R.T. Hepatitis C virus and hepatocarcinogenesis. Clin. Mol. Hepatol. 2012; 18: 347-56.Kwun H.J., Jung E.Y., Ahn J.Y., Lee M.N., Jang K.L. p53-depen-dent transcriptional repression of p21 (waf1) by hepatitis C virus NS3. J. Gen. Virol. 2001; 82: 2235-41.Hassan M., Ghozlan H., Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology. 2005; 333: 324-36.Hassan M., Selimovic D., Ghozlan H, Abdel-Kader O. Induction of high-molecular-weight (HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell. Signal. 2007; 19: 301-11.De Mitri M.S., Cassini R., Bagaglio S., Morsica G., Andreone P., Marino N. et al. Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. Liver Int. 2007; 27: 1126-33.Higgs M.R., Lerat H., Pawlotsky J.M. Hepatitis C virus-induced activation of P-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. 2013; 32: 4683-93.Benga W.J., Krieger S.E., Dimitrova M., Zeisel M.B., Parnot M., Lupberger J. et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology. 2010; 51: 43-53.Kim K., Kim K.H., Ha E., Park J.Y., Sakamoto N., Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009; 583: 2720-6.Maqbool M.A., Imache M.R., Higgs M.R., Carmouse S., Pawlotsky J.M., Lerat H. Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes. J. Virol. 2013; 87: 5523-39.Majumder M., Ghosh A.K., Steele R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/ waf1 gene expression in a p53-dependent manner. J. Virol. 2001; 75: 1401-7.Pavio N., Taylor D.R., Lai M.M. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J. Virol. 2002; 76: 1265-72.Erdtmann L., Franck N., Lerat H., Le Seyec J., Gilot D., Cannie I. et al. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J. Biol. Chem. 2003; 278: 18256-64.Moriyama M., Kato N., Otsuka M. Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A. Hepat. Int. 2007; 1: 302-10.Nahon P., SuttonA., RufatP., CharnauxN., MansouriA.,MoreauR. et al. A variant in myeloperoxidase promoter hastens the emer gence of hepatocellular carcinoma in patients with HCV-related cirrhosis. J. Hepatol. 2012; 56: 426-32.Gharib A.F., Karam R.A., Pasha H.F., Radwan M.I., Elsawy W.H. Polymorphisms of hemochromatosis, and alpha-1 antitrypsin genes in Egyptian HCV patients with and without hepatocellular carcinoma. Gene. 2011; 489: 98-102.Ishizu Y., Katano Y., Honda T., Hayashi K., Ishigami M., Itoh A. et al. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2012; 27: 1112-6.Wang Y., Kato N., Hoshida Y., Yoshida H., Taniguchi H., Goto T. et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003; 37: 65-71.Wei Y, Liu F., Li B., Chen X., Ma Y, Yan L. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a huge systematic review and meta-analysis. Dig. Dis. Sci. 2011; 56: 2227-36.Radwan M.I., Pasha H.F., Mohamed R.H., Hussien H.I., El-Khshab M.N. Influence of transforming growth factor-P1 and tumor necrosis factor-а genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012; 60: 271-6.Yuan J.M., Lu S.C., Van Den Berg D., Govindarajan S., Zhang Z.Q., Mato J.M. et al. Genetic polymorphisms in the methylenetetrahy-drofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology. 2007; 46: 749-58.Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T. et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res. 2006; 12: 4867-71.Abu Dayyeh B.K., Yang M., Fuchs B.C., Karl D.L., Yamada S., Sninsky J.J. et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011; 141: 141-9.Chen K., Song F., Calin G.A., Wei Q., Hao X., Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis. 2008; 29: 1306-11.Xu T., Zhu Y, Wei Q.K., Yuan Y., Zhou F., Ge Y Y. et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008; 29: 2126-31.Lo P.H., Urabe Y., Kumar V., Tanikawa C., Koike K., Kato N. et al. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. PLoS One. 2013; 11 (8): e61279.Miki D., Ochi H., Hayes C.N., Abe H., Yoshima T., Aikata H. et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nature Genet. 2011; 43: 797-800.Boccaccio V., Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int. 2014; 34 (Suppl. 1): 38-45.Aghemo A., Degasperi E., Rumi M.G., Galmozzi E., Valenti L., De Francesco R. et al. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Biomed. Res. Int. 2013; 2013: 580796.Николаева Л.И., Сапронов Г.В. Вирус гепатита С: мишени для терапии и новые лекарственные препараты. Вопросы вирусологии. 2012; 5: 10-5.Сапронов Г.В., Николаева Л.И. Новые перспективы персонифицированной терапии хронического вирусного гепатита С. Эпидемиология и инфекционные болезни. 2013; 3: 27-36.Bourliere M., Wendt A., Fontaine H., Hezode C., Pol S., Brono-wicki J.P. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int. 2013; 33 (Suppl. 1): 46-55.